These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 15251160)
21. [The role of ibandronate in the daily oncological practice]. Nagykálnai T Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006 [TBL] [Abstract][Full Text] [Related]
22. Ibandronate: its role in metastatic breast cancer. Cameron D; Fallon M; Diel I Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737 [TBL] [Abstract][Full Text] [Related]
23. Ibandronate: efficacy in the treatment of metastatic bone disease. Diel IJ Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036 [TBL] [Abstract][Full Text] [Related]
24. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. Menssen HD; Sakalová A; Fontana A; Herrmann Z; Boewer C; Facon T; Lichinitser MR; Singer CR; Euller-Ziegler L; Wetterwald M; Fiere D; Hrubisko M; Thiel E; Delmas PD J Clin Oncol; 2002 May; 20(9):2353-9. PubMed ID: 11981007 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Gordon DH Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990 [TBL] [Abstract][Full Text] [Related]
26. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study. Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162 [TBL] [Abstract][Full Text] [Related]
27. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. Pecherstorfer M; Diel IJ Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222 [TBL] [Abstract][Full Text] [Related]
28. Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial. Pivot X; Lortholary A; Abadie-Lacourtoisie S; Mefti-Lacheraf F; Pujade-Lauraine E; Lefeuvre C; Letessier S; Morvan P; Dür C; Frimat L Breast; 2011 Dec; 20(6):510-4. PubMed ID: 21727006 [TBL] [Abstract][Full Text] [Related]
29. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes. von Moos R; Caspar CB; Steiner R; Angst R; Inauen R; Schmieding K; Thürlimann B Onkologie; 2010; 33(8-9):447-50. PubMed ID: 20838060 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Hultborn R; Gundersen S; Ryden S; Holmberg E; Carstensen J; Wallgren UB; Killany S; Andreassen L; Carlsson G; Fahl N; Hatschek T; Sommer HH; Hessman Y; Hornmark-Stenstam B; Johnsborg S; Klepp R; Laino R; Niklasson LG; Rudenstam CM; Sundbeck A; Söderberg M; Tejler G Anticancer Res; 1999; 19(4C):3383-92. PubMed ID: 10629624 [TBL] [Abstract][Full Text] [Related]
31. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid. Yeh DC; Chen DR; Chao TY; Chen SC; Wang HC; Rau KM; Feng YH; Chang YC; Lee KD; Ou-Yang F; Kuo WH; Chang KJ; Lin YC; Tseng LM; Hou MF In Vivo; 2014; 28(5):1001-4. PubMed ID: 25189922 [TBL] [Abstract][Full Text] [Related]
32. Bone metabolism markers: Indicators of loading dose intravenous ibandronate treatment for bone metastases from breast cancer. Wang R; Zhang S; Jiang Z; Tian J; Wang T; Song S Clin Exp Pharmacol Physiol; 2017 Jan; 44(1):88-93. PubMed ID: 27716993 [TBL] [Abstract][Full Text] [Related]
33. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Macpherson IR; Bray C; Hopkins C; Hannon RA; Lewsley LA; Ritchie DM; Canney P Clin Breast Cancer; 2015 Apr; 15(2):117-27. PubMed ID: 25454689 [TBL] [Abstract][Full Text] [Related]
34. Bisphosphonates for cancer patients: why, how, and when? Body JJ; Mancini I Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223 [TBL] [Abstract][Full Text] [Related]
35. A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain. Heras P; Hatzopoulos A; Heras V; Kritikos N; Karagiannis S; Kritikos K Am J Ther; 2011 Sep; 18(5):340-2. PubMed ID: 20634675 [TBL] [Abstract][Full Text] [Related]
36. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899 [TBL] [Abstract][Full Text] [Related]
37. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Vassiliou V; Kalogeropoulou C; Christopoulos C; Solomou E; Leotsinides M; Kardamakis D Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):264-72. PubMed ID: 17084550 [TBL] [Abstract][Full Text] [Related]
38. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Chow E; Meyer RM; Ding K; Nabid A; Chabot P; Wong P; Ahmed S; Kuk J; Dar AR; Mahmud A; Fairchild A; Wilson CF; Wu JSY; Dennis K; Brundage M; DeAngelis C; Wong RKS Lancet Oncol; 2015 Nov; 16(15):1463-1472. PubMed ID: 26489389 [TBL] [Abstract][Full Text] [Related]
39. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. Hoskin P; Sundar S; Reczko K; Forsyth S; Mithal N; Sizer B; Bloomfield D; Upadhyay S; Wilson P; Kirkwood A; Stratford M; Jitlal M; Hackshaw A J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26242893 [TBL] [Abstract][Full Text] [Related]
40. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. Pecherstorfer M; Ludwig H; Schlosser K; Buck S; Huss HJ; Body JJ J Bone Miner Res; 1996 May; 11(5):587-93. PubMed ID: 9157773 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]